Pluristyx partners with leading biotechnology and pharmaceutical companies, academic institutions and research organizations to support and accelerate the development and commercialization of revolutionary therapeutics.
In July 2023, Pluristyx and Stem Genomics announced the closing of an equity investment and strategic partnership in Stem Genomics. Through the partnership, the companies will offer a unified pathway to allow customers to evaluate the genomic stability of Pluristyx’s pluripotent stem cell (PSC) lines using Stem Genomics’ iCS-digital™ PSC assay.
Advanced Regenerative Manufacturing Institute (ARMI)
In July 2023, Pluristyx announced an agreement with the Advanced Regenerative Manufacturing Institute | BioFabUSA to manufacture and commercialize Pluristyx’s clinical-grade reprogrammed induced Pluripotent Stem Cells (iPSCs). Pluristyx, Inc. today announced an agreement with the Advanced Regenerative Manufacturing Institute | BioFabUSA to manufacture and commercialize Pluristyx’s clinical-grade reprogrammed induced Pluripotent Stem Cells (iPSCs).
California Institute for Regenerative Medicine
In June 2023, Pluristyx announced its’ acceptance as an Industry Resource Partner (IRP) with the California Institute for Regenerative Medicine (CIRM). This partnership provides CIRM awardees with improved access to Pluristyx / panCELLa’s highly-characterized and genetically-modified induced Pluripotent Stem Cells (iPSCs) containing industry-leading FailSafe™ and iACT Stealth Cell ™ technologies.
In May 2023, Pluristyx and Stemmatters announced a collaboration focused on the advancement of next generation of iPSC-derived Mesenchymal Stem Cells (iMSCs), engineered iMSCs and biological products produced from conditionally immortalized iMSC lines that include exosomes and conditioned media. The collaboration will focus on the large-scale manufacturing of iMSC banks for both non-clinical and clinical research projects, offering an end-to-end comprehensive range of services to clients developing iPSC-based technologies.
Pluristyx, Inc., with expertise in gene-edited induced pluripotent stem cells (iPSCs) and National Resilience, Inc. (Resilience), a technology-focused biomanufacturing company dedicated to broadening access to complex medicines today, today announced a collaboration agreement to streamline the transition of promising iPSC-derived therapies from the benchtop to the bedside.